Preclinical anti-cancer program sold to Bayer Schering Pharma Bayer Schering Pharma will assume full development and commercialization rights Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program......

Strategic decision to divest oncology projects Eight anti-cancer projects in preclinical stage and clinical phase I Martinsried based 4SC will assume full development and commercialization rights Nycomed today agreed with 4SC on the sale of a major part of Nycomed’s R&D projects in the field of oncology......

Intercell AG to acquire Iomai Corporation to expand late stage product pipeline and strengthen leadership in vaccine innovation in a fully recommended share/cash transaction for USD 6.60 per share of Iomai's common stock representing a fully diluted equity value of Iomai of approximately USD 189 million (EUR 122 million)...

Sepracor acquires exclusive development, marketing and commercialisation rights to the Ciclesonide franchise in the United States Ciclesonide is the active ingredient in the ALVESCO® Inhalation Aerosol for asthma and the Omnaris™ Nasal Spray for allergic rhinitis ALVESCO® and Omnaris™ are FDA-approved and are on track to be launched in 2008 Agreement is in alignment with Nycomed’s strategy to cooperate with the best partners for its key brands in the United States Partnership between Nycomed and Sepracor provides a good strategic fit for both companies Nycomed has granted Sepracor, Inc......